- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:54 | US FDA accepts supplemental Biologics License Application for Merck's Enflonsia | ||
| 12:54 | Saatchi & Saatchi Health London appoint Pedro Rosa and May Leen Wong | ||
| Do | Number of women in England receiving HRT on the NHS more than doubles | ||
| Do | The AI concierge: how biopharma is evolving HCP service | ||
| Mi | Johnson & Johnson announces change in senior leadership role | ||
| Mi | Navigating patient experience data in rare disease | ||
| Di | Lilly's olomorasib gets FDA Breakthrough Therapy designation for pancreatic cancer | ||
| Di | Congresses have evolved. Has your strategy? | ||
| Mo | Novartis' Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer | ||
| Mo | Patient-centred healthcare communications: why co-creation drives better creative ideas | ||
| 31.07. | AbbVie's Rinvoq approved by European Commission for non-segmental vitiligo | ||
| 31.07. | Forging a connection through creativity | ||
| 30.07. | Inizio launches Connected Insights | ||
| 30.07. | Pfizer announces phase 3 results for nonsegmental vitiligo treatment | ||
| 29.07. | Cases of skin cancer set to reach 263,000 in 2035 according to new report | ||
| 29.07. | Former Serviceplan Health Managing Partner launches new consultancy | ||
| 28.07. | Havas Lynx expands Claire Knapp's remit to oversee Havas Lynx New York | ||
| 28.07. | Johnson & Johnson commits $5.5bn to end remaining talc litigation | ||
| 27.07. | EMA recommends granting marketing authorisation approval for Nezglyal | ||
| 27.07. | MAD World Summit 2026: where the future of workplace well-being takes centre stage | ||
| 24.07. | AstraZeneca's Trixeo recommended by CHMP for approval in EU for asthma | ||
| 24.07. | ELRIG appoints Hitesh Sanganee and Marcus Schindler to Scientific Advisory Board | ||
| 23.07. | Pfizer's Talzenna plus Xtandi gets FDA Priority Review for metastatic prostate cancer | ||
| 23.07. | Stoke Therapeutics appoints Thomas McCauley as Chief Scientific Officer | ||
| 22.07. | Takeda's zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.